Sanofi (SNY) US announces a broad expansion of its Insulins Valyou Savings Program by offering a 30-day supply of any Sanofi insulin for $35 to all patients in the US with a valid prescription. The program, first created for people without health insurance, will be available to all Americans regardless of insurance status, including those with commercial insurance or Medicare, to ensure affordable access to these critical medicines. Sanofi’s expanded Insulins Valyou Savings Program now ensures no American needs to pay more than $35 per month for their Sanofi insulins. The expanded program will cover all Sanofi insulins and will be implemented nationwide. This initiative builds on Sanofi’s longstanding commitment to access and affordability. Under this expansion, every American will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for a fixed monthly price of $35. The expanded Insulins Valyou Savings Program will be available to patients beginning January 1, 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Trump announcement gives big pharma ‘light at end of the tunnel,’ says Jefferies
- Trump to impose 100% tariff on drugs unless manufacturer building U.S. plant
- Sanofi’s Dupixent Advances in EU with Positive CHMP Opinion
- Sanofi’s Promising Pipeline and Strategic Positioning Justify Buy Rating
- Regeneron, Sanofi announce CHMP opinion recommending Dupixent approval